Author

J. L. Berrigan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

A. I. Kuehne· 1 shared A. K. Mishra· 1 shared A. S. Herbert· 1 shared A. Wang· 1 shared A.-L. Barabasi· 1 shared C. J. Donahue· 1 shared C. K. Hjorth· 1 shared C. O'Leary· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. I. Kuehne

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Crimean-Congo Hemorrhagic Fever Survivors Elicit Protective Non-Neutralizing Antibodies that Target 11 Overlapping Regions on Viral Glycoprotein GP38

O. S. Shin, S. R. Monticelli, C. K. Hjorth, V. Hornet, M. Doyle, D. Abelson, A. I. Kuehne, A. Wang, R. R. Bakken, A. K. Mishra, M. Middlecamp, E. Champney, L. Stuart, D. P. Maurer, J. Li, , J. S. McLellan

The paper identifies non-neutralizing antibodies from CCHFV survivors that target multiple regions on GP38, showing protective efficacy in rodent models.

bioRxiv · Mar 2, 2024Immunology

Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo.

J. Patten, P. T. Keiser, D. M. Gysi, G. Menichetti, H. Mori, C. J. Donahue, X. Gan, I. F. do Valle, K. Geoghegan-Barek, M. Anantpadma, R. Boytz, J. L. Berrigan, S. Hulsey-Stubbs, K. T. Ayazika, C. O'Leary, , R. A. Davey

The paper identifies 389 small molecules and 813 host targets that inhibit SARS-CoV-2 infection through in vitro and in vivo testing, using computational integration of drug activity and cellular networks.

bioRxiv · Apr 20, 2021 · PreprintMicrobiology